Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock

Zacks Investment Research highlights Fortress Biotech (FBIO) as a "Fast-Paced Momentum at a Bargain" stock, noting its recent price increase of 6.5% over the past four weeks and 7.7% over the past 12 weeks, coupled with a beta of 1.76 and a Momentum Score of A. The stock also has a Zacks Rank #2 (Buy) due to upward earnings estimate revisions and trades at a Price-to-Sales ratio of 0.93, suggesting it is undervalued despite its momentum.

Analysis

Fortress Biotech (FBIO) has been identified by Zacks Investment Research as a compelling investment candidate, aligning with their 'Fast-Paced Momentum at a Bargain' screening criteria. The biopharmaceutical company's stock has demonstrated notable recent price appreciation, registering a 6.5% increase over the past four weeks and a 7.7% rise over the preceding twelve weeks. This positive price trajectory is supported by a high beta of 1.76, signifying that the stock typically moves with 76% greater volatility than the overall market, and a Zacks Momentum Score of 'A', indicating favorable conditions for continued momentum. Furthermore, FBIO carries a Zacks Rank #2 (Buy), which is attributed to an upward trend in earnings estimate revisions by analysts. Despite these strong momentum indicators, the stock appears to be attractively valued, trading at a Price-to-Sales (P/S) ratio of 0.93. This P/S multiple suggests that investors are paying 93 cents for every dollar of the company's sales, indicating potential undervaluation and room for further upside.

Key Decisions for Investors

• Investors seeking exposure to momentum stocks with seemingly attractive valuations may find FBIO a candidate for consideration, supported by its Zacks Rank #2 (Buy) and strong price performance.
• The current Price-to-Sales ratio of 0.93 suggests potential undervaluation; however, ongoing monitoring of earnings estimate revisions and actual sales growth will be critical to confirm the sustainability of the investment thesis.
• Given FBIO's high beta of 1.76, investors should be prepared for greater price volatility compared to the broader market and factor this into risk assessment and position sizing.